Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069477 | 1.00 | DGAT1 (0.38) | DGAT1ALDH1A1POLBMAPTCA12 | |
| SCHEMBL15998215 | 0.82 | MAPT (0.30) | MAPT | |
| SCHEMBL10171878 | 0.82 | MAPT (0.46) | ALDH1A1MAPTPKMKDM4ETSHR | |
| SCHEMBL18878199 | 0.82 | DGAT1 (0.35) | DGAT1ALDH1A1MAPTCA12CA1 | |
| SCHEMBL22874322 | 0.81 | DGAT1 (0.38) | DGAT1PKMKDM4ETSHRTDP1 | |
| SCHEMBL22874331 | 0.81 | DGAT1 (0.38) | DGAT1PKMKDM4ETSHRTDP1 | |
| SCHEMBL27959952 | 0.80 | MGAM (0.30) | ALDH1A1 | |
| SCHEMBL21492510 | 0.79 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL12600077 | 0.79 | DGAT1 (0.37) | DGAT1ALDH1A1POLBMAPTPKM | |
| SCHEMBL19749962 | 0.79 | DGAT1 (0.37) | DGAT1ALDH1A1POLBMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697241-B1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3150608-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2937350-A1 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2280973-B1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2012-11-28 | — | — | EP | disclosed |
| WO-2012142523-A2 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012039787-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012039791-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037038-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2009132135-A1 | 1' -SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| EP-1513531-B1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE SPA (IT) | 2009-10-21 | — | — | EP | disclosed |
| US-7491825-B2 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RICERCHE S.P.A. (IT) | 2009-02-17 | — | — | US | disclosed |
| US-20060205712-A1 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | MENARINI RIEERCHE S.P.A. (IT) | 2006-09-14 | — | — | US | disclosed |
| EP-1513531-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Menarini Ricerche S.p.A. (IT) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103671-A1 | BASIC NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM | MENARINI RICERCHE S.P.A. (IT) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205712-A1 | Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom | BDKRB2, BDKRB1, AGTR2 | DGAT1 4744/4885ALDH1A1 4613/4885POLB 3623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.